MedTrace Logo

A Study of Lasmiditan (LY573144) Over Four Migraine Attacks

NCT03670810 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 1633

Last updated 2022-07-29

Study results available
· View outcomes & findings →

Summary

The reason for this study is to see how effective and safe the study drug known as lasmiditan is in the acute treatment of 4 migraine attacks with or without aura.

Conditions

Interventions

DRUG

Lasmiditan

Administered orally.

DRUG

Placebo

Administered orally.

Sponsors & Collaborators

Principal Investigators

  • Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST) · Eli Lilly and Company

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-06-24
Primary Completion
2020-06-12
Completion
2021-07-08
FDA Drug
Yes

Countries

  • United States
  • Austria
  • Belgium
  • China
  • Czechia
  • Denmark
  • France
  • Germany
  • Hungary
  • India
  • Italy
  • Mexico
  • Netherlands
  • Russia
  • Spain
  • Switzerland
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03670810 on ClinicalTrials.gov